Clinical Trial Update: KZR-261 in Subjects With Advanced Solid Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study of KZR-261 in subjects with advanced/metastatic solid tumors was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• KZR-261 (KZR-261)

Snippet

Sponsor: Kezar Life Sciences, Inc. | Conditions: Advanced/Metastatic Solid Tumor | Phase 1 | Status: TERMINATED | Results posted: 2025-12-19